ClinicalTrials.Veeva

Menu

Early rhBNP on Myocardial Work in Patients With STEMI

Shanghai Jiao Tong University logo

Shanghai Jiao Tong University

Status and phase

Unknown
Phase 4

Conditions

ST-Segment Elevated Myocardial Infarction

Treatments

Drug: rhBNP
Drug: Control

Study type

Interventional

Funder types

Other

Identifiers

NCT04157868
EARLY MYO-myocardial work

Details and patient eligibility

About

The study intends to evaluate the efficacy of early rhBNP on myocardial work in patients with anterior ST-segment elevation myocardial infarction after percutaneous coronary intervention

Enrollment

200 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

    1. Anterior myocardial infarct (anterior myocardial infarct is defined as persistent chest pain for 30 mins at least, with ST-segment elevation of at least 0.2 mV in two or more contiguous precordial leads) within 12 hours after onsets of symptom;

    2. No contraindication for rhBNP;

    3. Left anterior descending (LAD) as culprit vessel, with TIMI 0-1 grade.

Exclusion criteria

  • 1.Cardiogenic shock (systolic BP <90mmHg after fluid infusion or systolic BP<100mmHg after vasoactive drugs);

    1. History of myocardial infarct;

    3.Severe arrhythmia: with III degree A-V block ,atrial fibrillation,ventricular fibrillation,ventricular tachycardia;

    1. Any history of severe renal or hepatic dysfunction (hepatic failure, cirrhosis, portal hypertension or active hepatitis); neutropenia or thrombocytopenia; known acute pancreatitis;

    2. Pregnant or lactating;

    3. life expectancy≤12 months;

    4. Inability to follow the protocol and comply with follow-up requirements or any other reason the investigator feels would place the patient at increased risk;

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

200 participants in 2 patient groups, including a placebo group

rhBNP
Experimental group
Description:
rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.
Treatment:
Drug: rhBNP
Control
Placebo Comparator group
Description:
Saline intra-coronary injection 0.15ml/kg loading dose, with same intravenous injection speed for 72 hour after randomization.
Treatment:
Drug: Control

Trial contacts and locations

0

Loading...

Central trial contact

Song Ding, MD,Ph.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems